结缔组织生长因子在阿魏酸钠干预单侧输尿管梗阻大鼠肾脏的表达

背景:结缔组织生长因子是转化生长因子β1的下游效应因子,其异常升高在肾纤维化发生、发展中起关键作用,干预结缔组织生长因子在肾脏的异常表达可改善肾脏的纤维化.目的;从mRNA和蛋白水平观察阿魏酸钠对单侧输尿管梗阻大鼠肾组织结缔组织生长因子的影响,以及阿魏酸钠干预后大鼠肾间质纤维化的变化,并与氯沙坦进行比较.设计:随机对照动物实验.单位:四川大学华西医院肾脏科和四川大学公共卫生学院.材料:实验选用雄性成年健康SD大鼠24只,购于四川大学实验动物中心(实验用阿魏酸钠片由成都亨达药业有限公司惠赠,批号:050302).兔抗大鼠结缔组织生长因子多克隆抗体(Santa Cruz).Wcstern印迹设备购自美国BioRAD,DNA Engine OpaconTM实时荧光定量PCR仪购自美国MJResearch公司.方法:实验于2006-05/12在四川大学公共卫生学院医学检验研究室完成(生物安全级别:BSL-1).将24只大鼠随机分为4组:模型组、阿魏酸钠组、氯沙坦组和假手术组,每组6只.前3组按既往文献方法建立单侧输尿管梗阻模型,假手术行假手术.术后24 h开始.阿魏酸钠治疗组予阿魏酸钠溶液150 mg/(kg·d)灌胃;氯沙坦组予氯沙坦溶液20 mg/(kg·d)灌胃,其余2组灌胃同体积生理盐水.术后14 d处死大鼠,取部分肾组织用于分析.主要观察指标:采用荧光定量PCR,Western印迹方法从mRNA和蛋白质水平检测肾组织结缔组织生长因子的表达情况;行HE,Masson染色观察肾间质病理学改变.结果:①阿魏酸钠对肾组织结缔组织生长因子表达的影响:模型组术后14 d结缔组织生长因子mRNA和蛋白的表达较假手术组明显升高,而阿魏酸钠治疗组与模型组比较有明显的下降(P<0.05),同时,与氯沙坦组比较,差异无显著性意义(P>0.05).②阿魏酸钠干预后肾组织病理学改变:单侧输尿管梗阻术后第14天苏木精-伊红染色和Masson染色可见间质中多量炎性细胞浸润和小管、间质的改变,间质胶原的沉积等肾纤维化的病变;单侧输尿管梗阻大鼠经阿魏酸钠治疗治疗后,阿魏酸钠治疗改善了肾组织的纤维化(P<0.05),与氯沙坦组比较,差异无显著性意义(P>0.05).结论:①阿魏酸钠对单侧输尿管梗阻所致的大鼠肾脏纤维化的形成有明显的抑制作用,其作用机制可能与其降低结缔组织生长因子的表达有关.②阿魏酸钠抑制肾脏纤维化作用与氯沙坦相当.

Expression of connective tissue growth factor following Sodium Ferulate in rats with unilateral ureteral obstruction

BACKGROUND: Connective tissue growth factor (CTGF) is a kind of factor that can mediate downstream action of transforming growth factor-β 1 (TGF- β 1). The upregulation of connective tissue growth factor expression plays an important role in pathological changes of renal interstitial fibrosis.OBJECTIVE: To explore the effect of Sodium Ferulate on the expression of CTGF mRNA and protein in rats with unilateral ureteral obstruction (UUO) and pathological changes of renal interstitial fibrosis, and to compare with Losartan.DESIGN: Randomized and controlled animal trial.SETTING: Department of Nephrology, West China Hospital of Sichuan University, and College of Public Health, Sichuan University.MATERIALS: Twenty-four healthy adult male SD rats were selected from the Experimental Animal Center of Sichuan University. Sodium Ferulate was provided by Sichuan Hengda Pharmacy Co, Ltd (No. 050302); rabbit anti-rat CTGF by Santa Cruz; Western blotting by BioRAD, USA; DNA Engine OpticonTM real-time fluorescent quantitation PCR device by MJ Research, USA.METHODS: The experiment was performed at Research Laboratory of Clinical Medicine (grade BSL-1), College of Public Health, Sichuan University from May to December 2006. Twenty-four healthy rats were randomly divided into 4 groups (n=6): UUO model group, Sodium Ferulate group, Losartan group, and sham-operation group. According to the previous protocol, UUO models were established in UUO model group, Sodium Ferulate group, and Losartan group, and the other rats were subjected to sham operation. From the first day after UUO, Sodium Ferulate group was intragastrically (i.g.)administrated with 150 mg/kg/d Sodium Ferulate; Losartan group was administrated ig. with 20 mg/kg/d. Losartan; UUO and sham operation groups were administrated i.g. with matching normal saline. All rats were executed 14 days after UUO to harvest partial renal tissues. All experimental procedure was accorded with animal ethical standards.MAIN OUTCOME MEASURES: The mRNA and protein expressions of CTGF were quantified by real-time PCR and Western blot. The pathological changes of renal interstitial tissues were observed by hematoxylin/eosin (HE) and Masson staining.RESULTS: Twenty-four rats were included in final analysis. Fourteen days after UUO, CTGF mRNA and protein expressions in UUO model group were significantly increased compared with sham operation group, but the expressions in Sodium Ferulate group were significantly lower than model group (P < 0.05). Compared with Losartan treated group, there was no significant difference (P > 0.05). HE and Masson staining showed inflammatory cell infiltration and tubular and interstitial changes as well as collagen deposition in renal interstitial tissues on day 14 after UUO. Sodium Ferulate obviously improved the renal pathological changes in UUO rats (P < 0.05), and the effect was similar to Losartan (P > 0.05).CONCLUSION: Sodium Ferulate inhibits UUO-induced renal interstitial fibrosis. This action, similar to the effect of Losartan, might be due to downregulation of CTGF expression.